Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).

Authors :: Chung, Christine H.
Moorhead, Graydon
Haradhvala, Nicholas
Parida, Laxmi
Li, Jiannong
Slebos, Robbert
Song, Xiaofei
Chaudhary, Ritu
Poole, Maria
Park, Robin
Kirtane, Kedar
Steuer, Conor Ernst
Saba, Nabil F.
Bhateja, Priyanka
Rocco, James William
Bonomi, Marcelo Raul
Danysh, Brian
Getz, Gad
Tan, Aik-choon
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6053-6053, 1p
Publication Year :: 2023

Full Text Access

Tools